Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bellerophon Therapeutics, Inc.BLPH · Entity 108982 | Director | June 07, 2023 | June 09, 2023 |
| STRYKER CORPSYK · Entity 369 | VP, Chief Med&Scientific Off. | February 12, 2014 | February 14, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bellerophon Therapeutics, Inc.
Report date June 07, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2033-06-07 | Direct | 14,607 |
Reported balance
After 2023-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-07 · Grant · Disposed 14,607 · Balance 14,607 F1: This option was approved by the Compensation Committee of the Board of Directors of Bellerophon Therapeutics, Inc., on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the options were granted, which was approved by stockholders on June 7, 2023. F2: This option vests in full on June 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was approved by the Compensation Committee of the Board of Directors of Bellerophon Therapeutics, Inc., on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the options were granted, which was approved by stockholders on June 7, 2023.
F2: This option vests in full on June 7, 2024.
STRYKER CORP
Report date February 12, 2014 · Filed February 14, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option granted 02/12/2014 (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.14 · Expires 2024-02-11 | Direct | 18,980 |
Reported balance
After 2014-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2014-02-12 · Grant · Acquired 18,980 · Balance 18,980 F1: Employee stock option granted pursuant to the Stryker Corporation 2011 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Employee stock option granted pursuant to the Stryker Corporation 2011 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2023 Filed Jun 9, 2023 16:11 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Options (Right to Buy) · Derivative | 14,607 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001104659-23-069908 · tm2318251-5_4seq1.xml · derivative · entry 1 Bruder Scott P · CIK 0001411721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,607 Underlying: Common Stock · 14,607 shares Expires 2033-06-07 F1 · date: This option was approved by the Compensation Committee of the Board of Directors of Bellerophon Therapeutics, Inc., on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the options were granted, which was approved by stockholders on June 7, 2023. F2 · derivative.exercise_date: This option vests in full on June 7, 2024. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 16:45 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Options (right to buy) · Derivative | 29,000 | $1.52 Strike: $1.52 | $44,080.00 |
DisclosureSEC source: 0001415889-23-002455 · form4-02142023_040202.xml · derivative · entry 1 Bruder Scott P · CIK 0001411721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2033-02-10 Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:10 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Options (right to buy) · Derivative | 21,828 | $3.10 Strike: $3.10 | $67,666.80 |
DisclosureSEC source: 0001415889-22-000187 · form4-01042022_040110.xml · derivative · entry 1 Bruder Scott P · CIK 0001411721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,966 Underlying: Common Stock · 21,828 shares Expires 2031-12-31 Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 16:02 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 6,509 | $10.12 Strike: $10.12 | $65,871.08 |
DisclosureSEC source: 0001600132-20-000099 · wf-form4_160011374518224.xml · derivative · entry 1 Bruder Scott P · CIK 0001411721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,138 Underlying: Common Stock · 6,509 shares Expires 2030-09-10 Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 16:51 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 46,266 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001600132-19-000128 · wf-form4_156987665937588.xml · derivative · entry 1 Bruder Scott P · CIK 0001411721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,482 Underlying: Common Stock · 46,266 shares Expires 2029-09-26 Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 16:52 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 38,216 | $2.27 Strike: $2.27 | $86,750.32 |
DisclosureSEC source: 0001600132-18-000071 · wf-form4_152840473035562.xml · derivative · entry 1 Bruder Scott P · CIK 0001411721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,216 Underlying: Common Stock · 38,216 shares Expires 2028-06-04 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 16:59 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001600132-17-000103 · wf-form4_150645958329659.xml · derivative · entry 1 Bruder Scott P · CIK 0001411721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-09-21 F1 · derivative.exercise_date: This option was granted on September 22, 2017. This option vests in three equal annual installments over a three-year period from the date of grant. Read SEC document |
| February 12, 2014 Filed Feb 14, 2014 20:25 UTC | STRYKER CORP SYK · Entity 369 | GrantEmployee Stock Option granted 02/12/2014 (right to buy) · Derivative | 18,980 | $0.00 Strike: $81.14 | $0.00 |
DisclosureSEC source: 0000310764-14-000036 · edgar.xml · derivative · entry 1 Bruder Scott P · CIK 0001411721 · VP, Chief Med&Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,980 Underlying: Common Stock · 18,980 shares Expires 2024-02-11 F1 · derivative.exercise_date: Employee stock option granted pursuant to the Stryker Corporation 2011 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant. Read SEC document |
| February 13, 2013 Filed Feb 15, 2013 22:14 UTC | STRYKER CORP SYK · Entity 369 | GrantRestricted Stock Units granted 02/13/2013 · Derivative | 3,906 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000310764-13-000028 · edgar.xml · derivative · entry 2 Bruder Scott P · CIK 0001411721 · VP, Chief Med&Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,906 Underlying: Common Stock · 3,906 shares Expires not disclosed F2 · derivative.exercise_price: Each retsricted stock unit represents a contingent right to receive one share of Stryker common stock. F2 · price: Each retsricted stock unit represents a contingent right to receive one share of Stryker common stock. F3 · derivative.exercise_date: The Restricted Stock Units vest as to 100% of the shares on February 13, 2016. Vesting will be accelerated in the event of termination of employment by reason of disability or death but will otherwise cease upon termination of employment with Stryker. F3 · derivative.expiration_date: The Restricted Stock Units vest as to 100% of the shares on February 13, 2016. Vesting will be accelerated in the event of termination of employment by reason of disability or death but will otherwise cease upon termination of employment with Stryker. Read SEC document |
| February 13, 2013 Filed Feb 15, 2013 22:14 UTC | STRYKER CORP SYK · Entity 369 | GrantEmployee Stock Option granted 02/13/2013 (right to buy) · Derivative | 23,510 | $64.01 Strike: $64.01 | $1,504,875.10 |
DisclosureSEC source: 0000310764-13-000028 · edgar.xml · derivative · entry 1 Bruder Scott P · CIK 0001411721 · VP, Chief Med&Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,510 Underlying: Common Stock · 23,510 shares Expires 2023-02-12 F1 · derivative.exercise_date: Employee stock option granted pursuant to the Stryker Corporation 2006 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.